Format

Send to

Choose Destination
See comment in PubMed Commons below
FEBS Lett. 2013 Dec 11;587(24):3921-7. doi: 10.1016/j.febslet.2013.10.042. Epub 2013 Nov 7.

MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer.

Author information

1
Department of Clinical Laboratory Medicine, Shanghai Tenth People's Hospital of Tongji University, Shanghai 200072, China; Department of Laboratory Medicine, Chongqing Zhongshan Hospital, Chongqing 400013, China.

Abstract

Mitogen-activated protein kinase kinase 1 (MAP2K1/MEK1) as well as Yes-associated protein (YAP), the downstream effector of Hippo signaling pathway, is linked to hepatocarcinogenesis. However, little is known about whether and how MEK1 interacts with YAP. In this study, we find that MEK1-YAP interaction is critical for liver cancer cell proliferation and maintenance of transformed phenotypes both in vitro and in vivo. Moreover, MEK1 and YAP proteins are closely correlated in human liver cancer samples. Mechanistically, inhibition of MEK1 by both PD98059 and U0126 as well as RNAi reduces beta-transducin repeat containing E3 ubiquitin protein ligase (BTRC), which acts as a potential endogenous YAP protector.

KEYWORDS:

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; BTRC; Cell signaling; ERK1/2; HCC; Hippo pathway; IF; IHC; MTT; TMA; hepatocellular carcinoma; immunofluorescence; immunohistochemistry; tissue microarray analysis

PMID:
24211253
DOI:
10.1016/j.febslet.2013.10.042
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center